These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16463553)

  • 41. [Calcium pros and cons: long term use of bisphosphonates. Bisphophonate should not be used for long term].
    Mori S
    Clin Calcium; 2011 Oct; 21(10):1547-51. PubMed ID: 21960243
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathologizing old age: the case of osteoporosis.
    Grob GN
    MD Advis; 2011; 4(2):20-2, 24-7. PubMed ID: 21637178
    [No Abstract]   [Full Text] [Related]  

  • 43. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
    MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206
    [No Abstract]   [Full Text] [Related]  

  • 44. When to stop treating the bones.
    Mandell BF
    Cleve Clin J Med; 2011 Sep; 78(9):563. PubMed ID: 21885688
    [No Abstract]   [Full Text] [Related]  

  • 45. Ibandronic acid IV: new formulation. Unconvincing evidence.
    Prescrire Int; 2008 Feb; 17(93):10. PubMed ID: 18354845
    [No Abstract]   [Full Text] [Related]  

  • 46. Recognition of women at risk for fracture and intervention with fast-acting therapies.
    Derman R
    Int J Fertil Womens Med; 2006; 51(4):183-90. PubMed ID: 17184104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ask the doctor. I'm looking for information on Prolia and Reclast as alternatives to Boniva.
    Robb-Nicholson C
    Harv Womens Health Watch; 2011 Nov; 19(3):8. PubMed ID: 22276325
    [No Abstract]   [Full Text] [Related]  

  • 48. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2024 Jul; 66(1706):105-112. PubMed ID: 38981102
    [No Abstract]   [Full Text] [Related]  

  • 50. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study.
    Miller PD; Ragi-Eis S; Mautalen C; Ramirez F; Jonkanski I
    Bone; 2011 Dec; 49(6):1317-22. PubMed ID: 21945737
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevention of postmenopausal osteoporosis and associated fractures: Clinical evaluation of the choice between estrogen and bisphosphonates.
    Al-Azzawi F
    Gynecol Endocrinol; 2008 Nov; 24(11):601-9. PubMed ID: 19031214
    [No Abstract]   [Full Text] [Related]  

  • 53. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: do bisphosphonates relieve pain caused by acute osteoporotic vertebral compression fractures?
    Jenkinson E
    Emerg Med J; 2011 Mar; 28(3):242-3. PubMed ID: 21367798
    [No Abstract]   [Full Text] [Related]  

  • 54. Denosumab (prolia) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756
    [No Abstract]   [Full Text] [Related]  

  • 55. [The benefit from ibandronate in the treatment of postmenopausal osteoporosis].
    Málek Z
    Vnitr Lek; 2007 Oct; 53(10):1114-8. PubMed ID: 18072438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age.
    Ettinger MP; Felsenberg D; Harris ST; Wasnich R; Skag A; Hiltbrunner V; Wilson K; Schimmer RC; Miller PD
    J Rheumatol; 2005 Oct; 32(10):1968-74. PubMed ID: 16206354
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis].
    Reginster JY
    Rev Med Liege; 2006 Nov; 61(11):783-6. PubMed ID: 17191748
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [New bone density conservation agents for osteoporosis under research and development: Minodronic acid].
    Takata S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():417-20. PubMed ID: 18161142
    [No Abstract]   [Full Text] [Related]  

  • 59. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
    Bize R; Lamy O; Peytremann-Bridevaux I
    Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.